GlaxoSmithKline

GSK will pay up to £1.7billion to settle claims that its heartburn drug Zantac caused cancer, ending a five-year legal saga.

Jenna Fischer discusses breast cancer diagnosis and treatment; Nobel Prize in chemistry awarded to David Baker, Demis Hassabis, and John Jumper for computational protein design; human placentas used to heal burns; medical transport helicopter crash kills three in Kentucky; Trump secretly sent COVID tests to Putin in 2020; Danco Laboratories seeks FDA approval for mifepristone in miscarriage management; FDA rejects dasiglucagon for congenital hyperinsulinism; physical activity reduces depression in cancer patients; COVID linked to increased risk of heart attack, stroke, and death; U.S. to screen travelers from Rwanda for Marburg virus; high suicide attempts among LGBTQ+ women; 3% of U.S. high school students identify as transgender; CDC survey shows high rates of sadness and suicide ideation among adolescents; RSV vaccine sales drop; GSK's RSV vaccine efficacy declines; hundreds of unknown viruses found on toothbrushes and shower heads; exoskeleton manufacturer refuses to help paraplegic; over 250 entities pledge to stock naloxone for opioid overdoses.

GSK's Phase III AReSVi-006 trial of Arexvy RSV vaccine showed 62.9% cumulative efficacy against lower respiratory tract disease over three seasons, with 67.4% against severe cases. The vaccine's safety profile aligned with previous data, and common adverse events included pain at the injection site, fatigue, and headaches.

DelveInsight's Menopause Market Insights, Epidemiology, and Market Forecast-2034 report analyzes market trends, epidemiology, and emerging therapies in the US, EU4, UK, and Japan. Key companies include GlaxoSmithKline, Pfizer, Bayer, and others. The market size was ~USD 10,968 million in 2022, with hormonal therapy dominating but expected to decline as non-hormonal therapies gain prevalence. Notable therapies include VEOZAH, a non-hormonal treatment approved by the FDA in 2023.

GSK's Arexvy, the first RSV vaccine, showed 62.9% cumulative efficacy over three RSV seasons against RSV-LRTD in adults 60+; 67.4% against severe RSV-LRTD. Efficacy includes different RSV subtypes, age groups, and medical conditions. Revaccination may be needed to maintain protection. The vaccine was approved in the US in May 2023 for adults 60+ and is under review for those 50-59 at risk.

GSK and Pfizer see US RSV vaccine sales decline; Sage discontinues Alzheimer’s drug post late-stage trial failure.

GSK's Arexvy vaccine showed 63% efficacy against RSV over three seasons, with a decline to 48% in the third season. The CDC does not recommend a second dose, but GSK suggests revaccination may be needed. Arexvy is the only RSV vaccine with three-season data, and GSK will provide further data to help determine future schedules.

Article references highlight studies on risk of bias in in vivo research, comparison of treatment effects between animal experiments and clinical trials, validation of therapeutic targets through human genetics, and the decline in pharmaceutical R&D efficiency. Key topics include Mendelian randomization for drug target validation, clinical development success rates, and the use of genetic evidence in drug approval. The article also mentions the integration of genetic data into electronic health records and the potential of RNA-based therapeutics.